- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03267901
Effects of Daily Walnut Intake Among the Subjects With Metabolic Syndrome
Effects of Daily Walnut Intake Among the Subjects With Metabolic Syndrome in South Korea
Investigators planed to conduct a randomized, controlled, crossover trial to examine the effects of daily walnuts intake among Korean subjects with metabolic syndrome. Primary objective of this study was to investigate the effects of daily walnut intake on changes of metabolic syndrome indices in Koreans with metabolic syndrome age over 30 years old. This study was consisted of four periods: run-in, first intervention, wash-out, and second intervention phases. As 16 weeks of first intervention period began after the run-in phase, the subjects were randomly assigned into one of two groups: walnut group and control group. Participants in walnut group consumed 45 grams of walnuts on a daily basis and participants in control group were provided iso-caloric white bread for first 16 weeks. After the first intervention and wash-out period (6 weeks), second intervention which is crossover of first intervention was started during the next 16 weeks. Anthropometric measurements and biochemical analyses were done at the beginning and the end of each intervention (0, 16, 22, and 38 weeks of trial). Habitual diet was randomly observed using 3-day diet record once during each phase.
Investigators expected to evaluate 1)effects of walnut ingestion on reverting metabolic syndrome to normal status especially by reducing waist circumference and improving serum levels of triglyceride and high-density lipoprotein, 2)beneficial effects of daily walnut consumption on changes of body composition in the subjects with metabolic syndrome, and 3)regulatory effects of daily walnut intake on inflammatory markers and diabetic markers.
Studieoversigt
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Seoul, Korea, Republikken, 07327
- ICAN Nutrition Education and Research
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria: at least three out of five metabolic syndrome components
- waist circumference (WC) >90 cm for men and >80 cm for women
- hypertension (DBP ≥85 and <110 mm Hg)
- hyperglycemia (≥100 mg/dL)
- elevated plasma TG concentrations (≥150 mg/dL)
- decreased plasma HDL-C concentrations (<40 mg/dL for men and <50 mg/dL for women)
Exclusion Criteria:
- the presence of morbid obesity (BMI ≥40)
- the use of any medication for the control of blood pressure, glucose, or lipid metabolism
- a medical history of hypocaloric diet consumption within the past year
- gastrointestinal tract disorders
- post-menopausal women
- smokers
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Walnut-Control
|
45 g of walnut / iso-caloric white bread
|
|
Eksperimentel: Control-Walnut
|
45 g of walnut / iso-caloric white bread
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
changes of waist circumference
Tidsramme: after 16 weeks of daily walnut consumption
|
Waist circumferences (cm) were obtained at the midpoint between the lowest rib and the iliac crest and rounded to the nearest 0.1 cm after inhalation and exhalation.
|
after 16 weeks of daily walnut consumption
|
|
changes of blood triglyceride level
Tidsramme: after 16 weeks of daily walnut consumption
|
Serum triglycerides (mg/dL) levels were measured by an enzymatic-colorimetric method.
|
after 16 weeks of daily walnut consumption
|
|
changes of blood high-density lipoprotein cholesterol levels
Tidsramme: after 16 weeks of daily walnut consumption
|
High density lipoprotein cholesterol (mg/dL) levels were determined by a homogeneous enzymatic-colorimetric method.
|
after 16 weeks of daily walnut consumption
|
|
changes of blood pressure
Tidsramme: after 16 weeks of daily walnut consumption
|
Blood pressure (mmHg) was measured on the right arm using an up-load blood pressure monitor with participants in a comfortably seated position after at least a 5-minute rest.
|
after 16 weeks of daily walnut consumption
|
|
changes of blood glucose level
Tidsramme: after 16 weeks of daily walnut consumption
|
Blood glucose levels (mg/dL) were measured using blood glucose monitor and test stripts from the finger tip.
|
after 16 weeks of daily walnut consumption
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
changes of total cholesterol level
Tidsramme: after 16 weeks of daily walnut consumption
|
Serum total cholesterol levels (ml/dL) were measured by an enzymatic-colorimetric method.
|
after 16 weeks of daily walnut consumption
|
|
changes of serum apolipoprotein B level
Tidsramme: after 16 weeks of daily walnut consumption
|
Serum apolipoprotein B (ml/dL) was measured using a turbidimetric immunoassay.
|
after 16 weeks of daily walnut consumption
|
|
changes of serum adiponectin level
Tidsramme: after 16 weeks of daily walnut consumption
|
Blood adiponectin (ug/mL) levels were measured using ELISA.
|
after 16 weeks of daily walnut consumption
|
|
changes of serum leptin level
Tidsramme: after 16 weeks of daily walnut consumption
|
Blood leptin (ug/mL) levels were measured using ELISA.
|
after 16 weeks of daily walnut consumption
|
|
changes of serum insulin level
Tidsramme: after 16 weeks of daily walnut consumption
|
Serum insulin (μU/mL) was measured with a commercially available kit, the ultrasensitive insulin ELISA kit using an Epoch microplate spectrophotometer.
|
after 16 weeks of daily walnut consumption
|
|
changes of low-density lipoprotein cholesterol level
Tidsramme: after 16 weeks of daily walnut consumption
|
Low-density lipoprotein cholesterol levels (ml/dL) were determined by a homogeneous enzymatic-colorimetric method.
|
after 16 weeks of daily walnut consumption
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CWC-2016-MetS
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Metabolisk syndrom
-
Consorcio Centro de Investigación Biomédica en...Hospital General Universitario Gregorio Marañon; Universidad Complutense... og andre samarbejdspartnereIkke rekrutterer endnuLeverfibrose/NASH | MASH - Metabolic Dysfunction-Associated Steatohepatitis | MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseSpanien
-
Rivus Pharmaceuticals, Inc.RekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatitisForenede Stater
-
Madrigal Pharmaceuticals, Inc.RekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatitisForenede Stater
-
Shanghai East HospitalRekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatitisKina
-
Southern California Institute for Research and...Ikke rekrutterer endnuMASH - Metabolic Dysfunction-Associated Steatohepatitis
-
Nabiqasim Industries (Pvt) LtdRekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatitisPakistan
-
Fondazione Policlinico Universitario Agostino Gemelli...RekrutteringMASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseItalien
-
Tangram Therapeutics PlcRekrutteringSunde deltagere | MASH - Metabolic Dysfunction-Associated SteatohepatitisDet Forenede Kongerige
-
University of Campania Luigi VanvitelliAfsluttetMASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseItalien
-
University Hospital, Basel, SwitzerlandIkke rekrutterer endnuKardiovaskulær-Kidney-metabolsk syndrom | Cradiovascular-Kidney-Liver-Metabolic (CKLM) syndromSchweiz
Kliniske forsøg med food
-
Purdue UniversityAfsluttetJernmangel | A-vitamin mangelSenegal
-
University of AberdeenRekrutteringKostændring | Bæredygtigt fødevareforbrugDet Forenede Kongerige
-
Rutgers, The State University of New JerseyAfsluttetMiljøeksponering | Udvalg af madForenede Stater
-
International Centre for Diarrhoeal Disease Research...Washington University School of MedicineUkendtErnæring | Mikrobiota | Supplerende madBangladesh
-
Ohio State UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RekrutteringDiabetes mellitus, type 2 | Dårlig ernæring | MadmangelForenede Stater
-
The Miriam HospitalNational Institute of General Medical Sciences (NIGMS)AfsluttetBetændelse | Fødevareusikkerhed | Fedme, barndom | Mentalt helbredForenede Stater
-
NYU Langone HealthAmerican Heart AssociationAfsluttet
-
Pennington Biomedical Research CenterOhio State UniversityAfsluttet
-
Medical University of South CarolinaWW InternationalAfsluttetFedme | VægttabForenede Stater
-
University of British ColumbiaAfsluttetHusholdningernes fødevaresikkerhedCambodja